NCORP of the Carolinas (Greenville Health System NCORP)

描述（由申请人提供）：卡罗来纳州NCORP的目标是1。每年至少招募300名患者参加NCI临床试验网络（NCTN）试验，包括癌症预防、控制、筛查/治疗后监测、治疗和成像临床试验。2. 提供社区意见，协助NCTN研究基地开展治疗、预防、控制和筛查、健康相关生活质量和癌症护理交付研究。3. 遵守协议并提交准确、及时的数据。4. 开展研究，让社区参与，包括少数族裔和服务不足的群体，并向社区通报通过研究取得的进展。5. 发展成为全国癌症护理研究领域的领导者。卡罗来纳州的NCORP将执行由NCTN小组赞助的临床试验研究的每个阶段，包括通过ITOR（转化肿瘤研究机构），基于基因测序的转化治疗。GHS临床数据仓库系统将为CCDR提供数据。格林维尔健康系统（GHS）癌症研究所参与了一个已经强大的生物标本库，并成为癌症基因组计划的成员（2013年7月接受拨款）。总的来说，北卡罗来纳州NCORP的组成部分和子组成部分是致力于治疗、预防、支持性护理和研究收益系统管理的组织。北卡罗来纳州的NCORP将最大限度地发挥其研究能力，以确保在癌症预防、诊断、治疗和护理/护理交付方面取得最高质量的进展。

DESCRIPTION (provided by applicant): The goals of NCORP of the Carolinas are 1. To enroll a minimum of 300 patients annually to NCI Clinical Trials Network (NCTN) trials including cancer prevention, control, screening/post-treatment surveillance, treatment, and imaging clinical trials. 2. To provide community input and assist the NCTN research bases in develop treatment, prevention, control and screening, health related quality of life and cancer care delivery research (CCDR). 3. To attain protocol compliance and submit accurate, timely data. 4. To conduct research by engaging the community, inclusive of minorities and the underserved, and informing the community of advances made through research. 5. To grow as a national leader in the realm of Cancer Care delivery research (CCDR). NCORP of the Carolinas will be perform every phase of clinical trial research sponsored by NCTN groups, including to include, via ITOR (Institution of Translational Oncology Research), translational treatment based on genetic sequencing. GHS Clinical data warehouse system will provide data for CCDR. The Greenville Health System (GHS) Cancer Institute participates in an already robust biospecimen repository and entered membership in the Cancer Genome project (grant accepted July 2013) Collectively the components and sub-components of NCORP of the Carolinas are organizations dedicated to treatment, prevention, supportive care, and system management for study accrual. NCORP of the Carolinas will maximize its research capabilities to ensure progress towards the highest quality of cancer prevention, diagnosis, treatment and care/care delivery.